CRNX logo

CRINETICS PHARMACEUTICALS IN

CRNXNASDAQ
πŸ† #854 by market capEarnings Feb 24 Β· PostUS Equity
$84.98β€”
Last available close Β· quote unavailable
πŸ””
Track CRNX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ–² 82.6%
1yβ–² 98.5%
🏦Market Cap
$9.01B
Small Cap
πŸ“ˆRevenue Growth (YoY)
2928.4%
High Growth
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
213.8x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
β€”
52-Week Range
$32.30 – $85.01
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
106.1M
Next Earnings
2027-02-24

Fundamentals Snapshot

Annual Revenue
$8M
Last Q Revenue
$25M
P/E Ratio
β€”
P/S Ratio
213.8x
EPS (TTM)
$-5.05
Dividend Yield
β€”
Dilution (1yr)
+2.8%
CRNX logo

CRINETICS PHARMACEUTICALS IN

CRNX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$8Mβ–² +640.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
86.0%β–Ό βˆ’14.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$517Mβ–² +52.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$384Mβ–² +67.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
94.1Mβ–² +2.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$53Mβ–Ό βˆ’$160M YoY
StockOtter Β· stockotter.space

About CRINETICS PHARMACEUTICALS IN

Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Hold
20 analysts
Strong Buy3
Buy3
Hold14
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.